What type of study is this?

September 19, 2025Journal of Dermatological TreatmentOpen Access

Apremilast in the treatment of pityriasis lichenoides et varioliformis acuta: a case report

View Full Paper

Ask AI

Bookmark

Apremilast demonstrated efficacy in treating pityriasis lichenoides et varioliformis acuta, improving skin lesions.
The treatment was well tolerated with no significant adverse effects reported during the case presentation.
Administration of apremilast, a phosphodiesterase-4 inhibitor, resulted in a positive clinical response in the patient.
Findings suggest potential for broader clinical application of apremilast in dermatological conditions.

Implication

Case report highlights efficacy and safety of apremilast, a PDE-4 inhibitor, in PLEVA treatment.

Abstract

Objectives To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/68d46fbd31b076d99fa69862 https://doi.org/10.1080/09546634.2025.2562302

View Full Paper

Ask AI

Bookmark

Implication

Case report highlights efficacy and safety of apremilast, a PDE-4 inhibitor, in PLEVA treatment.

Apremilast in the treatment of pityriasis lichenoides et varioliformis acuta: a case report

Key Points

Implication

Abstract

Discussion

Cite This Study

Apremilast in the treatment of pityriasis lichenoides et varioliformis acuta: a case report

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading